UBS Downgrades Crinetics (CRNX) to Neutral

July 28, 2026 2:38 AM

UBS analyst Ashwani Verma downgraded Crinetics (NASDAQ: CRNX) from Buy to Neutral with a price target of $85.00 (from $55.00).The ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found